UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| |
||||
| (Address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code:
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition. |
On February 28, 2023, Cytek Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2022. The press release is being furnished as Exhibit 99.1.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit Number |
Description of Exhibit | |
| 99.1 | Press release dated February 28, 2023 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |
The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Cytek Biosciences, Inc. | ||||||
| Date: February 28, 2023 | By: | /s/ Wenbin Jiang | ||||
| Wenbin Jiang, Ph.D. President and Chief Executive Officer | ||||||
Exhibit 99.1
Cytek Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
2022 revenue increased 32%, and 34% on constant currency basis, compared to prior year
Expects full year 2023 revenue of $225 million to $235 million, or growth of 37% to 43% over full year 2022
FREMONT, Calif., February 28, 2023 (GLOBE NEWSWIRE) — Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the fourth quarter and year ended December 31, 2022.
Recent Highlights
| • | Total revenue was $48.3 million, or $51.2 million on a constant currency basis, for the fourth quarter of 2022, representing 24% and 32% increases, respectively, over the corresponding period of 2021 |
| • | Total revenue was $164.0 million, or $171.8 million on a constant currency basis, for the full year 2022, representing 28% and 34% increases, respectively, over the full year 2021 |
| • | Net income was $3.7 million for the fourth quarter of 2022 and $2.5 million for the full year 2022, with adjusted EBITDA of $6.6 million for the fourth quarter of 2022 and $21.2 million for the full year 2022 |
| • | Expanded installed base to 1,670 instruments, with 169 instrument placements during the fourth quarter of 2022 and 560 placements during the full year 2022 |
| • | Acquired Flow Cytometry and Imaging Business from Luminex Corporation |
| • | Entered strategic partnership with Bio-Rad Laboratories to expand reagent capabilities, in line with Cytek’s strategy to further build out applications-driven reagents business |
“I am pleased with Cytek’s strong revenue growth and continued execution throughout 2022,” said Dr. Wenbin Jiang, CEO of Cytek Biosciences. “In addition to reporting strong financial results, we strengthened our organization with the addition of several executives to our team, and expanded our global presence. Today, we expanded our enterprise with the completed acquisition of Luminex’s Flow Cytometry and Imaging business and are excited to welcome this team to Cytek. Looking ahead to 2023, I am encouraged by our company’s position and confident in our continued success this year and beyond.”
Fourth Quarter 2022 Financial Results
Total revenue for the fourth quarter of 2022 was $48.3 million, a 24% increase over the fourth quarter of 2021, with continued demand across the full portfolio of Cytek’s offerings. On a constant currency basis, total revenue for the fourth quarter of 2022 was $51.2 million, a 32% increase over the fourth quarter of 2021.
Gross profit was $29.4 million for the fourth quarter of 2022, an increase of 24% compared to a gross profit of $23.6 million in the fourth quarter of 2021. Gross profit margin was 61% in the fourth quarter of 2022 compared to 61% in the fourth quarter of 2021. Adjusted gross profit margin in the fourth quarter of 2022 was 62% compared to 63% in the fourth quarter of 2021, after adjusting for stock-based compensation expense and amortization of acquisition-related intangibles.
Operating expenses were $29.3 million for the fourth quarter of 2022, a 31% increase from $22.3 million in the fourth quarter of 2021. The increase was primarily due to expenses to support continued growth of the business, including further investments in sales and marketing, R&D, and costs related to operating as a public company.
Research and development expenses were $9.7 million dollars for the fourth quarter of 2022 compared to $7.1 million dollars for the fourth quarter of 2021.
Sales and marketing expenses were $9.0 million dollars for the fourth quarter of 2022 compared to $8.3 million dollars for the fourth quarter of 2021.
General and administrative expenses were $10.5 million dollars for the fourth quarter of 2022, an increase from $6.9 million dollars for the fourth quarter of 2021.
Income from operations in the fourth quarter of 2022 was $0.1 million compared to income of $1.3 million in the fourth quarter of 2021. Net income in the fourth quarter of 2022 was $3.7 million compared to a loss of $1.2 million in the fourth quarter of 2021.
Adjusted EBITDA in the fourth quarter of 2022 was $6.6 million compared to $5.5 million in the fourth quarter of 2021, after adjusting for stock-based compensation expense and foreign currency exchange impacts.
Full Year 2022 Financial Results
Total revenue for the year ended December 31, 2022 was $164.0 million, a 28% increase over the year ended December 31, 2021. On a constant currency basis, total revenue for the full year 2022 was $171.8 million, a 34% increase over the full year 2021.
Gross profit was $101.0 million for the year ended December 31, 2022, an increase of 28% compared to a gross profit of $79.1 million in the year ended December 31, 2021. Gross profit margin was 62% in the year ended December 31, 2022 compared to 62% in the year ended December 31, 2021. Adjusted gross profit margin in the year ended December 31, 2022 was 63% compared to 63% in the year ended December 31, 2021, after adjusting for stock-based compensation expense and amortization of acquisition-related intangibles.
Operating expenses were $102.8 million for the year ended December 31, 2022, a 47% increase from $70.0 million in the year ended December 31, 2021. The increase was primarily due to expenses to support continued growth of the business, including further investments in sales and marketing, R&D, and costs related to operating as a public company.
Research and development expenses were $34.9 million dollars for the year ended December 31, 2022, compared to $24.4 million dollars for the year ended December 31, 2021.
Sales and marketing expenses were $33.2 million dollars for the year ended December 31, 2022, compared to $24.7 million dollars for the year ended December 31, 2021.
General and administrative expenses were $34.7 million dollars for the year ended December 31, 2022, an increase from $20.8 million dollars for the year ended December 31, 2021.
Loss from operations in the year ended December 31, 2022 was $1.8 million compared to income of $9.2 million in the year ended December 31, 2021. Net income in the year ended December 31, 2022 was $2.5 million compared to $3.0 million in the year ended December 31, 2021.
Adjusted EBITDA in the year ended December 31, 2022 was $21.2 million compared to $17.5 million in the year ended December 31, 2021, after adjusting for stock-based compensation expense and other non-recurring expenses.
Cash, cash equivalents, and short term investments were approximately $341.1 million as of December 31, 2022.
2023 Outlook
Cytek Biosciences expects full year 2023 revenue in the range of $225 million to $235 million, representing growth of 37% to 43% over full year 2022. This includes approximately $20 million of revenue contribution from the acquisition of Luminex’s Flow Cytometry and Imaging Business, which closed on February 28, 2023.
Webcast Information
Cytek will host a conference call to discuss the fourth quarter 2022 financial results on Tuesday, February 28, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A webcast of the conference call can be accessed at investors.cytekbio.com.
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s FSP platform includes its core instruments, the Aurora and Northern Lights™ systems; its cell sorter, the Aurora CS; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Other than Cytek’s Northern Lights CLC system and certain reagents for use therewith, which are available for clinical use in countries where the regulatory approval has been obtained from the local regulatory authorities, including China and the European Union, Cytek’s products are for research use only and not for use in diagnostic procedures. Please contact your local sales representatives for the status of local regulatory approval.
Cytek, Full Spectrum Profiling, FSP and Northern Lights are trademarks or registered trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and corporate Twitter account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and Twitter account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Statement Regarding Use of Non-GAAP Financial Information
Cytek has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the three- and twelve-month periods ended December 31, 2022 and December 31, 2021. Management believes that non-GAAP financial measures, including “Adjusted gross profit margin,” “Adjusted EBITDA” and revenue on a “constant currency basis” referenced above, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company’s core operating results. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans
and to benchmark the company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Cytek encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding Cytek Biosciences’ strategy to further build out its applications-driven reagents business, expectations for and confidence relating to Cytek’s continued success in 2023 and beyond and expectations that full year 2023 revenue will be in the range of $225 million to $235 million, including approximately $20 million of revenue contribution from the acquisition of the Luminex Flow Cytometry and Imaging Business (the “FCI Business”). These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to global economic and market conditions; Cytek’s ability to integrate the operations and employees of the acquired FCI Business and recognize the anticipated benefits of the of the transaction; Cytek Biosciences’ dependence on certain sole and single source suppliers; competition; market acceptance of Cytek Biosciences’ current and potential products; Cytek Biosciences’ ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and retain key employees; Cytek Biosciences’ ability to maintain, protect and enhance its intellectual property; and Cytek Biosciences’ ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations.
You should refer to the section entitled “Risk Factors” set forth in Cytek Biosciences’ Quarterly Report on Form 10-Q filed with the SEC on November 9, 2022, Cytek Biosciences’ Annual Report on Form 10-K to be filed with the SEC and other filings Cytek Biosciences makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek Biosciences’ forward-looking statements. Although Cytek Biosciences believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to Cytek Biosciences as of the date hereof, and Cytek Biosciences disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek Biosciences’ views as of any date subsequent to the date of this press release.
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
Investor Relations Contact:
Paul D. Goodson
Head of Investor Relations
pgoodson@cytekbio.com
Cytek Biosciences, Inc.
Consolidated Statements of Operations and Comprehensive Income
| Year ended | ||||||||
| (In thousands, except share and per share data) |
December 31, 2022 | December 31, 2021 | ||||||
| Revenue, net: |
||||||||
| Product |
$ | 148,600 | $ | 119,519 | ||||
| Service |
15,436 | 8,431 | ||||||
|
|
|
|
|
|||||
| Total revenue, net |
164,036 | 127,950 | ||||||
|
|
|
|
|
|||||
| Cost of sales: |
||||||||
| Product |
49,955 | 37,377 | ||||||
| Service |
13,107 | 11,429 | ||||||
|
|
|
|
|
|||||
| Total cost of sales |
63,062 | 48,806 | ||||||
|
|
|
|
|
|||||
| Gross profit |
100,974 | 79,144 | ||||||
| Operating expenses: |
||||||||
| Research and development |
34,858 | 24,442 | ||||||
| Sales and marketing |
33,230 | 24,710 | ||||||
| General and administrative |
34,690 | 20,835 | ||||||
|
|
|
|
|
|||||
| Total operating expenses |
102,778 | 69,987 | ||||||
|
|
|
|
|
|||||
| (Loss) income from operations |
(1,804 | ) | 9,157 | |||||
| Other income (expense): |
||||||||
| Interest expense |
(2,573 | ) | (1,741 | ) | ||||
| Interest income |
4,619 | 49 | ||||||
| Other expense, net |
1,018 | (1,527 | ) | |||||
|
|
|
|
|
|||||
| Total other expense, net |
3,064 | (3,219 | ) | |||||
|
|
|
|
|
|||||
| (Loss) income before income taxes |
1,260 | 5,938 | ||||||
| (Benefit from) provision for income taxes |
(1,224 | ) | 2,911 | |||||
|
|
|
|
|
|||||
| Net (loss) income |
$ | 2,484 | $ | 3,027 | ||||
|
|
|
|
|
|||||
| Less: net loss allocated to noncontrolling interests |
92 | (26 | ) | |||||
| Less: net income allocated to participating securities |
— | (3,001 | ) | |||||
|
|
|
|
|
|||||
| Net (loss) income attributable to common stockholders, basic and diluted |
$ | 2,576 | $ | — | ||||
|
|
|
|
|
|||||
| Net (loss) income attributable to common stockholders per share, basic |
$ | 0.02 | $ | — | ||||
|
|
|
|
|
|||||
| Net (loss) income attributable to common stockholders per share, diluted |
$ | 0.02 | $ | — | ||||
|
|
|
|
|
|||||
| Weighted-average shares used in calculating net (loss) income per share, basic |
134,510,831 | 76,741,858 | ||||||
|
|
|
|
|
|||||
| Weighted-average shares used in calculating net (loss) income per share, diluted |
138,562,111 | 81,542,729 | ||||||
|
|
|
|
|
|||||
| Comprehensive (loss) income: |
— | |||||||
| Net (loss) income |
$ | 2,484 | $ | 3,027 | ||||
| Foreign currency translation adjustment, net of tax |
(1,611 | ) | 832 | |||||
| Unrealized gain (loss) on marketable securities |
17 | — | ||||||
|
|
|
|
|
|||||
| Net comprehensive (loss) income |
$ | 890 | $ | 3,859 | ||||
|
|
|
|
|
|||||
Cytek Biosciences, Inc.
Consolidated Balance Sheets
| (In thousands, except share and per share data) |
December 31, 2022 |
December 31, 2021 |
||||||
| (unaudited) | (audited) | |||||||
| Assets |
||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 296,601 | $ | 364,618 | ||||
| Restricted cash |
2,899 | |||||||
| Short term investments |
44,548 | — | ||||||
| Trade accounts receivable, net |
48,864 | 29,760 | ||||||
| Inventories |
48,154 | 32,171 | ||||||
| Prepaid expenses and other current assets |
12,954 | 5,184 | ||||||
|
|
|
|
|
|||||
| Total current assets |
454,020 | 431,733 | ||||||
| Deferred income tax assets, noncurrent |
20,459 | 9,173 | ||||||
| Property and equipment, net |
13,682 | 5,851 | ||||||
| Operating lease right-of-use assets |
13,883 | — | ||||||
| Goodwill |
10,144 | 10,144 | ||||||
| Intangible assets, net |
4,331 | 4,739 | ||||||
| Other noncurrent assets |
2,957 | 1,665 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 519,476 | $ | 463,305 | ||||
|
|
|
|
|
|||||
| Liabilities, redeemable convertible preferred stock and stockholders’equity |
||||||||
| Current liabilities: |
||||||||
| Trade accounts payable |
$ | 4,805 | $ | 3,034 | ||||
| Legal settlement liability, current |
2,163 | 1,463 | ||||||
| Accrued expenses |
21,126 | 15,251 | ||||||
| Other current liabilities |
7,960 | 6,352 | ||||||
| Deferred revenue, current |
12,986 | 7,081 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
49,040 | 33,181 | ||||||
| Legal settlement liability, noncurrent |
15,596 | 13,745 | ||||||
| Deferred revenue, noncurrent |
13,124 | 9,790 | ||||||
| Operating lease liability, noncurrent |
12,312 | — | ||||||
| Long term debt |
2,271 | — | ||||||
| Other noncurrent liabilities |
1,587 | 1,204 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
$ | 93,930 | $ | 57,920 | ||||
|
|
|
|
|
|||||
| Commitments and contingencies |
||||||||
| Redeemable convertible preferred stock, $0.001 par value; 10,000,000 shares authorized, zero issued and outstanding as of December 31, 2022 and December 31, 2021; aggregate liquidation preference of zero as of December 31, 2022 and December 31, 2021. |
— | — | ||||||
| Stockholders’ equity: |
||||||||
| Common stock, $0.001 par value; 1,000,000,000 authorized shares as of December 31, 2022 and December 31, 2021, respectively; 135,365,381 and 133,749,663 issued and outstanding shares as of December 31, 2022 and December 31, 2021, respectively. |
135 | 126 | ||||||
| Additional paid-in capital |
442,887 | 423,625 | ||||||
| Accumulated deficit |
(17,030 | ) | (19,606 | ) | ||||
| Accumulated other comprehensive (loss) income |
(697 | ) | 897 | |||||
| Noncontrolling interest in consolidated subsidiary |
251 | 343 | ||||||
|
|
|
|
|
|||||
| Total stockholders’ equity |
$ | 425,546 | $ | 405,385 | ||||
|
|
|
|
|
|||||
| Total liabilities, redeemable convertible preferred stock and stockholders’ equity |
$ | 519,476 | $ | 463,305 | ||||
|
|
|
|
|
|||||
Cytek Biosciences, Inc.
Reconciliation of GAAP to Non-GAAP Measures
(Unaudited)
| Year ended | ||||||||
| December 31, 2022 | December 31, 2021 | |||||||
| (In thousands, except per share amounts) | ||||||||
| GAAP gross profit |
100,974 | 79,144 | ||||||
| Stock-based compensation |
2,855 | 1,508 | ||||||
| Amortization of acquisition-related intangible assets |
250 | 237 | ||||||
|
|
|
|
|
|||||
| Non-GAAP gross profit |
$ | 104,079 | $ | 80,889 | ||||
|
|
|
|
|
|||||
| Non-GAAP gross profit % |
63 | % | 63 | % | ||||
| GAAP operating expenses |
102,778 | 69,987 | ||||||
| Loss on lease exit cost |
— | (347 | ) | |||||
| Acquisition related expenses |
(218 | ) | (229 | ) | ||||
| Stock-based compensation |
(13,740 | ) | (5,078 | ) | ||||
| Amortization of acquisition-related intangible assets |
(481 | ) | (90 | ) | ||||
|
|
|
|
|
|||||
| Non-GAAP operating expenses |
$ | 88,339 | $ | 64,243 | ||||
|
|
|
|
|
|||||
| GAAP income (loss) from operations |
(1,804 | ) | 9,157 | |||||
| Loss on lease exit cost |
— | 347 | ||||||
| Acquisition related expenses |
218 | 229 | ||||||
| Stock-based compensation |
16,595 | 6,586 | ||||||
| Amortization of acquisition-related intangible assets |
731 | 327 | ||||||
|
|
|
|
|
|||||
| Non-GAAP income from operations |
$ | 15,740 | $ | 16,646 | ||||
|
|
|
|
|
|||||
| GAAP net income |
2,484 | 3,027 | ||||||
| Stock-based compensation |
16,595 | 6,586 | ||||||
| Amortization of acquisition-related intangible assets |
731 | 327 | ||||||
| Tax effect of items excluded from non-GAAP results |
710 | (160 | ) | |||||
|
|
|
|
|
|||||
| Non-GAAP net income |
$ | 20,520 | $ | 9,780 | ||||
|
|
|
|
|
|||||
| GAAP net income attributable to common stockholders |
2,576 | — | ||||||
| Loss on lease exit cost |
— | 347 | ||||||
| Acquisition related expenses |
218 | 229 | ||||||
| Stock-based compensation |
16,595 | 6,586 | ||||||
| Amortization of acquisition-related intangible assets |
731 | 327 | ||||||
| Tax effect of items excluded from non-GAAP results |
710 | (160 | ) | |||||
|
|
|
|
|
|||||
| Non-GAAP net income attributable to common stockholders |
$ | 20,830 | $ | 7,329 | ||||
|
|
|
|
|
|||||
| Average shares outstanding for calculation of non-GAAP net income per share (diluted) |
138,562,111 | 81,542,729 | ||||||
| GAAP Net Income |
2,484 | 3,027 | ||||||
| Depreciation and Amortization |
5,566 | 1,241 | ||||||
| (Benefits from) Provision for Income Taxes |
(1,224 | ) | 2,911 | |||||
| Interest Income |
(4,619 | ) | (49 | ) | ||||
| Interest Expense |
2,573 | 1,741 | ||||||
| Foreign currency exchange loss, net |
(426 | ) | 1,481 | |||||
| Loss on lease exit cost |
— | 347 | ||||||
| Stock-based compensation |
16,595 | 6,586 | ||||||
| Acquisition related expenses |
218 | 229 | ||||||
|
|
|
|
|
|||||
| Adjusted EBITDA |
$ | 21,167 | $ | 17,514 | ||||
|
|
|
|
|
|||||
Cytek Biosciences, Inc.
Reconciliation of GAAP to Non-GAAP Measures
(Unaudited)
| Three months ended | ||||||||
| December 31, 2022 | December 31, 2021 | |||||||
| (In thousands, except per share amounts) | ||||||||
| GAAP gross profit |
29,374 | 23,636 | ||||||
| Stock-based compensation |
641 | 717 | ||||||
| Amortization of acquisition-related intangible assets |
64 | 237 | ||||||
|
|
|
|
|
|||||
| Non-GAAP gross profit |
$ | 30,079 | $ | 24,590 | ||||
|
|
|
|
|
|||||
| Non-GAAP gross profit % |
62 | % | 63 | % | ||||
| GAAP operating expenses |
29,290 | 22,319 | ||||||
| Loss on lease exit cost |
— | (347 | ) | |||||
| Acquisition related expenses |
(218 | ) | (229 | ) | ||||
| Stock-based compensation |
(3,824 | ) | (2,290 | ) | ||||
| Amortization of acquisition-related intangible assets |
(123 | ) | (90 | ) | ||||
|
|
|
|
|
|||||
| Non-GAAP operating expenses |
$ | 25,125 | $ | 19,363 | ||||
|
|
|
|
|
|||||
| GAAP income (loss) from operations |
84 | 1,317 | ||||||
| Loss on lease exit cost |
— | 347 | ||||||
| Acquisition related expenses |
218 | 229 | ||||||
| Stock-based compensation |
4,465 | 3,007 | ||||||
| Amortization of acquisition-related intangible assets |
187 | 327 | ||||||
|
|
|
|
|
|||||
| Non-GAAP income from operations |
$ | 4,954 | $ | 5,227 | ||||
|
|
|
|
|
|||||
| GAAP net income |
3,718 | (1,165 | ) | |||||
| Stock-based compensation |
4,465 | 3,007 | ||||||
| Amortization of acquisition-related intangible assets |
187 | 327 | ||||||
| Tax effect of items excluded from non-GAAP results |
(18 | ) | (1,185 | ) | ||||
|
|
|
|
|
|||||
| Non-GAAP net income |
$ | 8,352 | $ | 984 | ||||
|
|
|
|
|
|||||
| GAAP net income attributable to common stockholders |
3,529 | (346 | ) | |||||
| Loss on lease exit cost |
— | 347 | ||||||
| Acquisition related expenses |
218 | 229 | ||||||
| Stock-based compensation |
4,465 | 3,007 | ||||||
| Amortization of acquisition-related intangible assets |
187 | 327 | ||||||
| Tax effect of items excluded from non-GAAP results |
(18 | ) | (1,185 | ) | ||||
|
|
|
|
|
|||||
| Non-GAAP net income attributable to common stockholders |
$ | 8,381 | $ | 2,379 | ||||
|
|
|
|
|
|||||
| GAAP Net Income |
3,718 | (1,165 | ) | |||||
| Depreciation and Amortization |
1,465 | 685 | ||||||
| (Benefits from) Provision for Income Taxes |
396 | 1,609 | ||||||
| Interest Income |
(2,626 | ) | (18 | ) | ||||
| Interest Expense |
687 | 492 | ||||||
| Foreign currency exchange loss, net |
(1,748 | ) | 295 | |||||
| Loss on lease exit cost |
— | 347 | ||||||
| Stock-based compensation |
4,465 | 3,007 | ||||||
| Acquisition related expenses |
218 | 229 | ||||||
|
|
|
|
|
|||||
| Adjusted EBITDA |
$ | 6,575 | $ | 5,481 | ||||
|
|
|
|
|
|||||
| Year Ended | Three Months Ended | |||||||
| December 31, 2022 | December 31, 2022 | |||||||
| Revenue, as reported |
164,036 | 48,336 | ||||||
| Non-GAAP constant currency |
171,793 | 51,184 | ||||||
| FX Impact [$] |
7,757 | 2,848 | ||||||
| FX Impact [%] |
4.7 | % | 5.9 | % | ||||